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OBJECTIVE: To quantify the quality of anticoagulation control
in routine medical care in the US: Long-term oral anticoagula-
tion reduces the risk of ischemic stroke in atrial ﬁbrillation but
only if the international normalized ratio (INR) is tightly con-
trolled between two and three. METHODS: A cohort study was
carried out in practices with no staff dedicated to anticoagula-
tion in four states. Charts of patients 18 years or older with atrial
ﬁbrillation and on an anticoagulant at least 60 consecutive days
between July 1, 2001 and June 30, 2002 were reviewed by
trained abstractors based on a standard form that covered mon-
itoring tests, results and patient outcomes. Data were entered via
touch-tone telephone (IVRS) and sensitivity analyses were per-
formed. RESULTS: Charts of 686 patients from 11 practices
(most internal or family medicine) and 67 practitioners were
reviewed. Mean age was 75 years; 53% male; 79% received war-
farin and mean interval between INR tests was 25 ± 22 days;
52% of physicians gave occasional face-to-face consultations in
connection with INR tests and 78% used clinical judgment alone
to adjust anticoagulant dose. A total of 53% of charts speciﬁed
a target INR of 2–3; patients spent 42% of the time with INRs
out of this range, most (27%) too low, yet the anticoagulant dose
was adjusted only a third of the times that INRs were out of
range. CONCLUSION: Concerted efforts to improve anticoag-
ulation have been made for more than a decade. Nevertheless,
despite increasing costs with frequent INR testing, there remain
severe deﬁciencies in the routine management of anticoagulation
in the US.
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Electronic data capture and remote study monitoring are being
implemented more frequently instead of traditional paper format
data collection methods for clinical trials. In outcomes research,
electronic data capture is only beginning to be used; few studies
report on the efﬁciency and feasibility of this technique. OBJEC-
TIVE: To assess the use of a telephone-based interactive voice
response data entry system (IVRS) used in a national chart
review study of anticoagulation management. METHODS: Fol-
lowing a one day training, nurses abstracted chart data using a
68 question (mostly closed) paper questionnaire. Anonymized
data were entered into the study database using a password-
protected IVRS accessed using a nationwide toll-free telephone
number available round the clock. RESULTS: Data entered by
10 study nurses were 100% complete for all 686 subjects
enrolled at four study sites in four US States (CA, MA, IN, NC).
Site initiated data corrections occurr for only 5% of subjects.
Time from database lock to a clean dataset was 10 working days.
Mean data entry time per subject was 16 minutes (min = 1; max
= 20) or 14 seconds per question. Key IVRS features designed to
facilitate use (e.g., question repeat, invalid answer prompt and
automatic re-entry to last question answered when entry was
interrupted) all worked well. CONCLUSIONS: Data capture
and remote study monitoring using IVRS is an efﬁcient and accu-
rate means of collecting detailed health economic data with a
minimum of oversight.
CARDIOVASCULAR DISEASE—Congestive Heart
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OBJECTIVE: The EPHESUS study demonstrated that aldos-
terone blockade with eplerenone decreased mortality in patients
with left ventricular systolic dysfunction (LVSD) and heart
failure after acute myocardial infarction (AMI). The EPHESUS
pharmacoeconomic analysis presented below was performed 
to evaluate the cost-effectiveness of eplerenone in the German
setting. METHODS: A total of 6632 patients with LVSD and
heart failure after AMI were randomized to eplerenone or
placebo and followed for a mean of 16-months. The co-primary
endpoints were all-cause death and the composite of cardiovas-
cular death/cardiovascular hospitalization. The evaluation of
resource use included hospitalizations, outpatient services, and
medications. Survival beyond the trial period was estimated
using data from the Framingham Heart Study, the Saskatchewan
Health database, and the Worcester Heart Attack Registry. The
incremental cost-effectiveness of eplerenone in cost per life-year
and quality-adjusted life-year gained was estimated. RESULTS:
The number of life-years gained with eplerenone was 0.1014
based on Framingham (95% CI: 0.0306–0.1740), 0.0636 with
Saskatchewan (95% CI: 0.0229–0.1038) and 0.1337 (95% CI:
0.0438–0.2252) with Worcester survival estimates. Total costs
were 961.2€ higher over the trial period in the eplerenone arm,
due to drug cost. The incremental cost-effectiveness ratio was
9,173€ per life-year gained with Framingham (98.8% under
50,000€ per-life year gained), 14,627.8€ with Saskatchewan, and
6,955.6€ with Worcester survival estimates. CONCLUSION:
Eplerenone is effective in reducing mortality and, in Germany, is
also cost-effective in increasing years of life for patients with
heart failure after AMI.
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OBJECTIVE: To assess the economic implications of implanta-
tion with a cardiac resynchronization device (CRT) versus
optimum pharmacologic treatment (OPT) for NYHA class III or
IV heart failure. METHODS: A discrete event simulation of the
course of heart failure was used to compare 1000 pairs of iden-
tical patients—one receiving CRT, the other OPT—for two years,
in terms of hospitalizations for heart failure, device-related com-
plications, NYHA class, and QOL (mortality assumed equal). All
input rates were derived by speciﬁc analyses of the data obtained
in the Multicenter InSync Randomized Clinical Evaluation
(MIRACLE). Changes in NYHA class were translated to QOL
via the corresponding distributions of Minnesota Living with
Heart Failure scores and the related utilities. Direct medical costs
to the NHS, reported in 2002 British Pounds Sterling (£), dis-
